Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 901–1,000 of 1,015
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 73
“In addition, melanoma patients whose tumors had elevated signaling activity in the WNT/β-catenin pathway lacked infiltrating T-cells, and murine studies have shown that WNT signaling can promote anti-PDL1/anti-CTLA-4 treatment failure in melanoma models (84).”
BackgroundBerghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 58
“there is little infiltration of CD8+ T cells, whereas this infiltration is important when the β-catenin pathway is not activated.(64) Similarly, the loss of anti-tumour protein”
BackgroundWiesweg, M., Mairinger, F. D., Reis, H., Goetz, M., Kollmeier, J., Misch, D., Stephan-Falkenau, S., Mairinger, T., Walter, R. F. H., Hager, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.015 · Cited by 60
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 66
“This process was initially identified in melanoma (99) in which tumor b-catenin levels interfered with DC and T cell intratumoral accumulation.”
BackgroundNishida, N. (2021) · Cancers · doi:10.3390/cancers13153666 · Cited by 66
“Furthermore, the transcriptional repression of CCL4 was attributed to the activation of activating transcription factor 3 (ATF3) as a result of the activation of the β-catenin signaling pathway [54].”
BackgroundKeller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 58
“showed that the PD-1 ligand, PD-L1, is expressed on melanoma cells with TILs, and indicates that IFNγ may increase PD-L1 expression; however, this study was performed in mice [83, 84].”
BackgroundKim, C. W., Chon, H. J., & Kim, C. (2021) · Cancers · doi:10.3390/cancers13194906 · Cited by 58
“β-catenin also suppressed the transcription of T-cell recruiting chemokine, CCL4, from dendritic cells and thus reduced the infiltration of CD8+ T cells within the TME in colon cancer and melanoma [48,49].”
BackgroundGeng, Q., Li, L., Shen, Z., Zheng, Y., Wang, L., Xue, R., Xue, W., Peng, M., & Zhao, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02132-7 · Cited by 58
“The main mechanism of this pathway is through the activation of recombinant activating transcription factor 3 (ATF3), which inhibits the expression of CCL4 and reduces the recruitment of CD103 dendritic cells, ultimately affecting the activation of CD8 T cells and limiting the efficacy of checkpoint inhibitors [50].”
BackgroundShi, Y., Wu, Z., Liu, S., Zuo, D., Niu, Y., Qiu, Y., Qiao, L., He, W. A., Qiu, J., Yuan, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52170-3 · Cited by 59
“Although WNT signaling was also closely related to tumor immune microenvironment 49 and could be potentially regulated by PRMT3, the components of WNT signaling were not identi fi ed as direct substrates of PRMT3 and WNT signaling is downstream of the PRMT3-IGF2BP1-HEG1-WNT axis 13 .”
Disentangling the relationship between tumor genetic programs and immune responsiveness
Bedognetti, D., Hendrickx, W., Ceccarelli, M., Miller, L. D., & Seliger, B. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.001 · Cited by 59
Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures
Stowman, A. M., Hickman, A. W., Mauldin, I. S., Mahmutovic, A., Gru, A. A., & Slingluff, C. L. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000439 · Cited by 58
Lee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 58
Li, C., Nguyen, V., Clark, K. N., Zahed, T., Sharkas, S., Filipp, F. V., & Boiko, A. D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813802116 · Cited by 56
“Furthermore, changes in the activity of Wnt network components have been shown to drive resistance of melanoma cells to the targeted and immune therapies (37, 38).”
BackgroundTargeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 59
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 58
Self-citationThe Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Koustas, E., Sarantis, P., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Biomolecules · doi:10.3390/biom10050666 · Cited by 57
“In a recent study, the authors highlighted the correlation between the WNT/β-catenin axis and the loss of T-cell gene expression in metastatic melanoma samples [91].”
BackgroundInfluentialPredictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar, R., Smyth, E. C., Peng, S., Yeong, J. P.-S., & Tan, P. B. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00763 · Cited by 57
Bellmunt, J., de Wit, R., Fradet, Y., Climent, M. A., Petrylak, D. P., Lee, J.-L., Fong, L. H., Necchi, A., Sternberg, C. N., O'Donnell, P. H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3089 · Cited by 60
Tiffen, J. C., Wilson, S. P., Gallagher, S. J., Hersey, P., & Filipp, F. V. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.003 · Cited by 56
“In support of this we identified downregulation of CD74 [GeneBank:972], an important chaperone that associates with MHC-II to regulate antigen presentation for immune responses, in addition to chemokines/chemokine receptors, CCL28 [GeneBank:56477], CCL3L1 [GeneBank:6349] and CCR7 [GeneBank:1236], known to activate T c…”
BackgroundTumor Microenvironment: No Effector T Cells without Dendritic Cells
Pfirschke, C., Siwicki, M. R., Liao, H.-W., & Pittet, M. J. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.007 · Cited by 60
“More recently, it was reported that b-catenin signaling activation, a melanoma-intrinsic oncogenic pathway, reduces intratumoral CD103+ DC numbers, which prevents tumor-specific T cell priming (Spranger et al., 2015).”
BackgroundClinical implications of tumor-intrinsic mechanisms regulating PD-L1
Prestipino, A., & Zeiser, R. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4810 · Cited by 52
Lei, A., Chen, L., Zhang, M., Yang, X., Xu, L., Cao, N., Zhang, Z., & Cao, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00422 · Cited by 67
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 61
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy
Li, J., & Stanger, B. Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1420 · Cited by 68
Sam, J., Colombetti, S., Fauti, T., Roller, A., Biehl, M., Fahrni, L., Nicolini, V., Perro, M., Nayak, T. K., Bommer, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575737 · Cited by 61
“These include the lack of tumor-specific antigens that are not expressed in primary epithelium (18), the local suppressive tumor microenvironment [characterized by expression of IL10, TGFb, IDO, COX-2, adenosine, and arginase, and presence of regulatory T-cells and myeloid-derived suppressor cells (19, 20)], and the p…”
BackgroundTumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 58
“by disrupting MHC class I [58,59]; JAK1/2 [59] and STK11 [60] mutations; WNT/b-catenin pathway alterations [61,62]; and PTEN loss [63].”
BackgroundAscierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
“The Wnt/β-catenin pathway has been identified as the first pathway that mediates immune exclusion and resistance to immunotherapies [123].”
BackgroundSelf-citationRole of EZH2 histone methyltrasferase in melanoma progression and metastasis
Mahmoud, F. A., Shields, B. D., Makhoul, I., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167291 · Cited by 57
“defective production of the chemokine CCL4 which in turn fails to recruit CD103C dendritic cells, required for T cell priming, to the melanoma microenvironment.(14) Hence, activation of the WNT/”
BackgroundMolecular insights into melanoma brain metastases
Westphal, D., Oliva, I. C. G., & Niessner, H. (2017) · Cancer · doi:10.1002/cncr.30594 · Cited by 71
“In metastatic melanoma, the lack of T-cell infiltration observed in some patients was caused by tumor-intrinsic b-catenin activation, resulting in decreased dendritic cells and thus T-cell recruitment.(100) Another study demonstrated that areas of metastatic melanoma cells with decreased PTEN and increased VEGF-A expr…”
BackgroundCancer vaccines: translation from mice to human clinical trials
Maeng, H. M., Terabe, M., & Berzofsky, J. A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.001 · Cited by 57
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
Cueto, F. J., del Fresno, C., & Sancho, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03146 · Cited by 56
Stoltzfus, C. R., Sivakumar, R., Kunz, L., Olin, B. E., Menietti, E., Speziale, D., Adelfio, R., Bacac, M., Colombetti, S., Perro, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726492 · Cited by 56
“Both tumor types also displayed a general paucity of DC1s, which have been shown to be critical for promoting anti-tumor CD8 T cell responses in draining lymph nodes and within tumor tissues after checkpoint blockade therapy (Broz et al., 2014; Mikucki et al., 2015; Spranger et al., 2015, 2017).”
BackgroundAnagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Bowman-Kirigin, J. A., Saunders, B. T., Desai, R., Wang, A. Z., Schaettler, M. O., Liu, C. J., Livingstone, A. J., Kobayashi, D. K., Durai, V., Kretzer, N. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0098 · Cited by 62
Carter, J. M., Chumsri, S., Hinerfeld, D. A., Ma, Y., Wang, X., Zahrieh, D., Hillman, D. W., Tenner, K., Kachergus, J. M., Brauer, H. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37806-0 · Cited by 55
In situ tumour arrays reveal early environmental control of cancer immunity
Ortiz-Muñoz, G., Brown, M. K., Carbone, C. B., Pechuan-Jorge, X., Rouilly, V., Lindberg, H., Ritter, A. T., Raghupathi, G., Sun, Q., Nicotra, T., et al. (2023) · Nature · doi:10.1038/s41586-023-06132-2 · Cited by 57
Luo, M., Wang, X., Wu, S., Yang, C., Su, Q., Huang, L., Fu, K., An, S., Xie, F., To, K. K. W., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01545-x · Cited by 57
“9,10 Therefore, patients with low TMB and low in fl ammatory gene markers usually exhibit poor clinical outcomes when receiving immunotherapies.”
BackgroundQiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“However, while some tumors are heavily infiltrated by T cells, others are not, which may be linked to the migration of dendritic cells and subsequent activation of T cells [52].”
BackgroundCancer vaccines as enablers of immunotherapy
Khleif, S. N., & Gupta, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02308-2 · Cited by 64
“Lastly, signaling pathways activated by oncogenic mutations, such as in Wnt/β-catenin, can decrease DC recruitment into the TME 39,40 .”
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 56
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Wang, D. Y., Eroglu, Z., Özgün, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0287 · Cited by 52
Heterogeneity of colon cancer: from bench to bedside
Merlano, M. C., Granetto, C., Fea, E., Ricci, V., & Garrone, O. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000218 · Cited by 56
Blazquez, R., Rietkötter, E., Wenske, B., Wlochowitz, D., Sparrer, D., Vollmer, E., Müller, G., Seegerer, J., Sun, X., Dettmer, K., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32742 · Cited by 53
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
Doo, D. W., Meza-Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920913798 · Cited by 52
Self-citationChen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., Yue, C., Chen, Y., Li, S., Turnquist, H. R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1024 · Cited by 57
“Despite advances in the clinical setting, the immune cellular network in the tumor microenvironment (TME) that mediates such therapy is not well understood.”
BackgroundInfluentialIdentification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Klempner, S. J., Bendell, J. C., Villaflor, V. M., Tenner, L. L., Stein, S., Rottman, J. B., Naik, G. S., Sirard, C. A., Kagey, M. H., Chaney, M. F., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0273 · Cited by 55
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 62
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 57
“More recently, B-catenin was involved in resistance to combination therapy (anti CTLA4 + anti-PD1) [149].”
BackgroundCancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 55
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126532 · Cited by 59
“CCL4 attracts CD103 + DCs through the receptor CCR5 [11].”
BackgroundNakagawara, K., Ando, M., Srirat, T., Mise‐Omata, S., Hayakawa, T., Ito, M., Fukunaga, K., & Yoshimura, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008665 · Cited by 53
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N. V., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 50
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
Yu, Y. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0581-0 · Cited by 57
The expanding landscape of inflammatory cells affecting cancer therapy
Weissleder, R., & Pittet, M. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0524-y · Cited by 55
Chen, W. S., Liang, Y., Zong, M., Liu, J. J., Kaneko, K., Hanley, K. L., Zhang, K., & Feng, G.-S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109974 · Cited by 50
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02981-w · Cited by 55
Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2109486 · Cited by 55
“…the efficacy of other immunotherapies including immune checkpoint blockade (ICB) (Broz et al. 2014; Salmon et al. 2016; Sanchez-Paulete et al. 2016; Spranger et al. 2015, 2017), suggest that DC vaccines should not be abandoned, but rather be refined either as a monotherapy or in combination with…”
BackgroundResistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Massi, D., Romano, E., Rulli, E., Merelli, B., Nassini, R., Logu, F. D., Bièche, I., Baroni, G., Cattaneo, L., Xue, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.012 · Cited by 53
“The inverse relationship between active b-catenin signalling and T-cell infiltration in both transgenic melanoma mouse models and human melanoma samples provided a first insight into a potential new mechanism of immune resistance [10].”
BackgroundInfluentialMelanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 59
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
de Santiago, I., Yau, C., Heij, L. R., Middleton, M. R., Markowetz, F. M., Grabsch, H. I., Dustin, M. L., & Sivakumar, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32186 · Cited by 51
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 59
Self-citationWnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
Stefanski, C. D., & Prosperi, J. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217844 · Cited by 59
“The direct injection of DCs increased the sensitivity to the immune checkpoint blockade [110,111].”
BackgroundKleeman, S. O., & Leedham, S. J. (2020) · Cancers · doi:10.3390/cancers12113355 · Cited by 62
“Additionally, Wnt signaling can protect cells from immune surveillance, thus restricting anti-tumoral immunity [12,13].”
BackgroundClark, N. M., Martinez, L. M., Murdock, S. J., DeLigio, J. T., Olex, A. L., Effi, C., Dozmorov, M. G., & Bos, P. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108482 · Cited by 55
“Cell intrinsic features of tumors dictate the composition of their immune infiltrate (Wellenstein and de Visser, 2018; Wang et al., 2017; Spranger et al., 2015).”
BackgroundGuo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3555 · Cited by 53
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer
Liu, Z., Wang, P., Wold, E. A., Song, Q., Zhao, C., Wang, C., & Zhou, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01799 · Cited by 50
Zhu, G., Wang, Y., Wang, B., Liu, W., Dong, S., Chen, E., Cai, J., Wan, J.-L., Du, J.-X., Song, L.-N., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.006 · Cited by 50
Regulation of Wnt receptor activity: Implications for therapeutic development in colon cancer
Zhong, Z. A., Michalski, M. N., Stevens, P. D., Sall, E. A., & Williams, B. O. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100782 · Cited by 52
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Carroll, T. M., Chadwick, J. A., Owen, R. P., White, M. J., Kaplinsky, J., Peneva, I., Frangou, A., Xie, P. F., Chang, J., Roth, A. J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.006 · Cited by 60
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 50
“Some resistance mechanisms are known and are driven by the biology of the melanoma, including downregulation of MHC molecules, loss of antigen expression, negative feedback causing PD-L1 upregulation in response to INF-γ production by T-cells and reduction in chemokine expression including CCL3, CSCL1, CXCL2 and CCL4…”
BackgroundCheckpoint Inhibitors and Their Application in Breast Cancer
Bedognetti, D., Maccalli, C., Bader, S. B. J. A., Marincola, F. M., & Seliger, B. (2016) · Breast Care · doi:10.1159/000445335 · Cited by 51
Potential applications of nanoparticles in cancer immunotherapy
Jia, Y., Omri, A., Krishnan, L., & McCluskie, M. J. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1245251 · Cited by 51
“patients with a pre-existing T-cell response against their tumor.(88) Li et al.”
BackgroundHigh-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions
Blaha, D. T., Anderson, S. D., Yoakum, D. M., Hager, M. V., Zha, Y., Gajewski, T. F., & Kranz, D. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0395 · Cited by 49
Self-citationRole of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
Hussain, S. M., Kansal, R. G., Alvarez, M. A., Hollingsworth, T., Elahi, A. H., Miranda‐Carboni, G. A., Hendrick, L. E., Pingili, A. K., Albritton, L. M., Dickson, P. V., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00594-0 · Cited by 49
Huang, Y., Sheng, H., Xiao, Y., Hu, W., Zhang, Z., Chen, Y., Zhu, Z., Wu, D., Cao, C., & Sun, J. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.034 · Cited by 52
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 54
Diverse Catalytic Reactions for the Stereoselective Synthesis of Cyclic Dinucleotide MK-1454
Benkovics, T., Peng, F., Phillips, E. M., An, C., Bade, R. S., Chung, C. K., Dance, Z. E. X., Fier, P. S., Forstater, J. H., Liu, Z., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12106 · Cited by 49
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 53
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas
Bognar, M., Vincendeau, M., Erdmann, T., Seeholzer, T., Grau, M., Linnemann, J. R., Ruland, J., Scheel, C., Lenz, P., Ott, G., et al. (2016) · Oncogene · doi:10.1038/onc.2015.493 · Cited by 48
Targeting invasive properties of melanoma cells
Arozarena, I., & Wellbrock, C. (2017) · FEBS Journal · doi:10.1111/febs.14040 · Cited by 53
“been linked to beta-catenin mutations in melanoma [58, 59] could also be a”
BackgroundYang, D., Zhao, J., Jia, M., & Song, X. (2017) · RSC Advances · doi:10.1039/c7ra05976k · Cited by 49
Chae, Y. K., Choi, W. M., Bae, W. H., Anker, J. F., Davis, A. A., Agte, S., Iams, W. T., Cruz, M. R. D. S., Matsangou, M., & Giles, F. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-19454-3 · Cited by 50
CCRK is a novel signalling hub exploitable in cancer immunotherapy
Mok, M. T. S., Zhou, J., Tang, W., Zeng, X., Oliver, A. W., Ward, S. E., & Cheng, A. S. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.008 · Cited by 53
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral, L., Coutzac, C., Kannouche, P. L., & Chaput, N. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.08.007 · Cited by 52
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49
“The transfer of in vitro preactivated DCs improves ICB efficacy in nonresponsive preclinical models of melanoma [60].”
BackgroundKobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 60
Kim, H., Jeong, S., Park, S., Lee, Y. J., Ju, Y. S., Kim, D., Song, G., Lee, J. H., Kim, S., Shin, J., et al. (2021) · Liver International · doi:10.1111/liv.14814 · Cited by 51
Cueto, F. J., del Fresno, C., Brandi, P., Combes, A. J., Hernández-García, E., Sánchez-Paulete, A. R., Enamorado, M., Bromley, C. P., Gómez, M. J., Conde‐Garrosa, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002054 · Cited by 50
Zhang, H., Bi, Y., Wei, Y., Liu, J., Kuerban, K., & Ye, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0825 · Cited by 52
“An article published in Nature has revealed that upregulation of endogenous b-catenin inhibits the production of CCL4, making it impossible to recruit BATF3 DCs into TME thereby preventing T-cell activation (15).”
BackgroundImmunotherapy failure in adrenocortical cancer: where next?
Cosentini, D., Grisanti, S., Volta, A. D., Laganà, M., Fiorentini, C., Perotti, P., Sigala, S., & Berruti, A. (2018) · Endocrine Connections · doi:10.1530/ec-18-0398 · Cited by 49
Apavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J., Hardy, M., Vincent, K., Brochu, S., Laverdure, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00979-2 · Cited by 57
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma
Roesch, A., Paschen, A., Landsberg, J., Helfrich, I., Becker, J. C., & Schadendorf, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.023 · Cited by 53
Okada-Iwasaki, R., Takahashi, Y., Watanabe, Y., Ishida, H., Saito, J.-I., Nakai, R., & Asai, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0938 · Cited by 48
“As theWnt/b-catenin pathway is also important in cancer cell differentiation (45) and antitumor immunity (46), future in vivo studies may reveal other effects of a TNKS inhibitor, which cannot be detected in in vitro studies.”
BackgroundSignaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“In melanoma, tumor-intrinsic active β-catenin signaling has been associated with the absence of type-1 DCs and effector CD8+ T cells in addition to resistance to anti-PD-L1 and anti-CTLA-4 therapy [27].”
Background
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.